Forest Pharmaceuticals, Inc. (FPI) can help you see the pharmaceuticals amidst the trees. The company develops, manufactures, and distributes a variety of prescription and OTC pharmaceutical products, including both branded and generic versions. Its product line includes Aerobid (asthma), Celexa and Lexapro (depression), Cervidil (cervical ripening), Tiazac (hypertension), and Namenda (Alzheimer's disease). FPI's products are marketed to physicians, hospitals, pharmacies, and managed care organizations in the US and Puerto Rico. The company, which operates manufacturing and packaging facilities in Missouri and Ohio, is a subsidiary of Forest Laboratories.

United Research Laboratories (URL), along with sister company Mutual Pharmaceutical (together known as URL/Mutual), manufactures generic medications and conducts research on existing drug formulas through agreements with other pharmaceutical companies. URL/Mutual has developed generic versions of drugs manufactured by King, Ortho-McNeil, Merck, and Berlex, among others. The company has also developed its own proprietary drug delivery systems. URL and Mutual Pharmaceuticals are subsidiaries of URL Pharma (formerly Pharmaceutical Holdings Corporation).

Adolor Corporation was founded in 1993 and is headquartered in Exton, Pennsylvania. Adolor Corporation is a biopharmaceutical company. The Company has specialized in the discovery and development of prescription pain management products. It has a number of product candidates in various stages of development, ranging from preclinical studies to pivotal clinical trials. On May 20, 2008, the United States Food and Drug Administration (FDA) approved the Company’s first product, ENTEREG (alvimopan), for the management of postoperative ileus following bowel resection surgery (POI). ENTEREG is specifically indicated to accelerate the time to upper and lower gastrointestinal recovery following partial large or small bowel resection surgery with primary anastomosis. The Company in collaboration with Glaxo Group Limited (Glaxo), launched ENTEREG in the United States in mid-2008.

4Life Research wants to protect the health of bipeds and quadrupeds alike. The multilevel marketing company manufactures nutritional supplements for humans and animals and sells them through its global network of independent distributors. The company's flagship product is Transfer Factor, a supplement made from egg yolks and cow colostrum that is meant to enhance the body's immune system. The firm makes Transfer Factor formulations for humans, dogs, cats, horses, and livestock. The privately-held company was founded in 1998 by CEO David Lisonbee, who had previous experience with multi-level marketing organizations.

ADVENTRX Pharmaceuticals, Inc. company was founded in 1995 is based in San Diego, California. ADVENTRX Pharmaceuticals, Inc., a biopharmaceutical company, focuses on in-licensing, developing, and commercializing proprietary product candidates for the treatment of cancer. Its lead product candidates include ANX-530, a novel emulsion formulation of chemotherapy drug vinorelbine to treat advanced non-small cell lung cancer as a single agent or in combination with cisplatin, as well as to treat advanced or metastatic breast cancer; and ANX-514, a novel emulsion formulation of the chemotherapy drug docetaxel for the treatment of breast, non-small cell lung, prostate, gastric, and head and neck cancers.

Prolexys Pharmaceuticals wouldn't necessarily characterize proteins as difficult to characterize, especially not if it's using the technology it developed. The biotech research firm's HySpec and HyNet are high-throughput systems for protein expression, purification, and analysis. Prolexys, formerly known as Myriad Proteomics, has also developed its own bioinformatics to put together protein interaction maps from the data generated by HySpec and HyNet. The company has been focusing on cancer research, working with groups such as Columbia University and the Tower Cancer Research Foundation to study advanced solid tumors. Myriad Genetics spun off Prolexys, which was founded in 2001, as a private company in 2003.

Solvay Pharmaceuticals is out to solve the medical maladies of the world. Part of Solvay SA's pharmaceuticals division, the US-based company develops, produces, and markets therapies for cardiovascular, gastroenterological, and neurological disorders. Solvay Pharmaceuticals also makes and markets flu vaccines and products for specialized markets such as women's and men's health. Its marketed products include AndroGel (testosterone replacement gel), Marinol (appetite stimulator and antiemetic), and ACEON (an antihypertension drug). Abbott Laboratories has agreed to acquire the Solvay Pharmaceuticals organization. Solvay Pharmaceuticals is led by CEO Stephen Hill.

Genmab was founded in 1999. Genmab analyzes genomes in its lab. The biotech company creates and develops human antibodies to treat such conditions as lymphoma and other cancers, as well as autoimmune and inflammatory diseases. It has assembled a portfolio of products under its HuMax brand that are in different stages of development, ranging from pre-clinical to late-stage trials. In addition to developing its HuMax products, Genmab is working to create products for conditions such as infectious diseases and vascular conditions. The company has licensing and development partnerships with several international pharmaceutical and biotech companies including GlaxoSmithKline, Amgen, Medarex, and Roche.

MDRNA, Inc. company was founded in 1983 and is headquartered in Bothell, Washington. MDRNA, Inc. operates as a biotechnology company focused on the development and commercialization of therapeutic products based on RNA interference (RNAi). The company seeks to improve human health by combining RNAi-based compounds and proprietary peptide- and liposomal-based drug delivery technologies to provide therapeutic options. MDRNA's multi-disciplinary portfolio of capabilities includes molecular biology, cellular biology, formulation expertise, peptide and alkylated amino acid chemistry, pharmacology, toxicology, and bioinformatics. The company is applying this expertise to a single, integrated drug discovery platform that would be the engine for its clinical pipeline and a versatile platform for establishing therapeutic partnerships. MDRNA is also building on new technologies, such as UsiRNAs that incorporate the non-nucleotide moiety Unlocked Nucleobase Analog (UNA) within the siRNA molecule, that might lead to safer and more effective RNAi-based therapeutics. The company combines expertise in siRNA science with proven delivery platforms and a growing IP portfolio, positioning MDRNA as an RNAi therapeutics company and a value-added collaborator for its research partners.

Dragon Pharmaceutical is looking to build a pharmaceutical empire in the PRC. Headquartered in Canada, the company has production facilities within mainland China that manufacture active pharmaceutical ingredients (APIs), intermediates, and finished formulations. It sells its bulk APIs and intermediates, which are used in antibiotic formulations, both in China and internationally (mainly in India). Its finished products (sold only in China) are primarily injectable cephalosporin antibiotics. In 2007 Dragon Pharmaceutical divested its biotech division in order to focus on its core antibiotic operations. CEO Yanlin Han holds nearly half of the company's stock and is seeking to buy the balance.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.